MED1 and neoplasm: Using ZR-75-1 and BT-474 mouse tumor xenograft models, we showed that trastuzumab and fulvestrant as single agents or in combination could also significantly inhibit the activation of MED1 and that their combination resulted in a much stronger inhibition than fulvestrant alone in work with BT-474 tumor xenograft model.